Drug Type Small molecule drug |
Synonyms Ganetespib (USAN) + [3] |
Target |
Mechanism HSP90 inhibitors(Heat shock 90kDa proteins inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H20N4O3 |
InChIKeyRVAQIUULWULRNW-UHFFFAOYSA-N |
CAS Registry888216-25-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acute Lymphoblastic Leukemia | Phase 2 | GB | - | |
Acute Lymphoblastic Leukemia | Phase 2 | DK | - | |
Acute Lymphoblastic Leukemia | Phase 2 | - | - | |
Acute Myeloid Leukemia | Phase 2 | - | - | |
Myelodysplastic Syndromes | Phase 2 | - | - | |
Acute Lymphoblastic Leukemia | Phase 1 | GB | - | |
Acute Lymphoblastic Leukemia | Phase 1 | DK | - | |
Acute Lymphoblastic Leukemia | Phase 1 | - | - | |
Acute Myeloid Leukemia | Phase 1 | - | - | |
Myelodysplastic Syndromes | Phase 1 | - | - |
Phase 2 | Breast Cancer Neoadjuvant | 233 | (ejvgrcalno) = oroxppsrrz nhnooejcvv (tcexptondi ) | - | 01 Dec 2022 | ||
Standard NAC control | (ejvgrcalno) = uskoijsuih nhnooejcvv (tcexptondi ) | ||||||
Phase 1/2 | 12 | (Phase 1: 100 mg/m2 Ganetespib, 80 mg/m2 Paclitaxel) | tegfpmlrbm(iqijnsojdr) = iruforulkc lthvbjjibq (wiihtkfhhb, sfwczroeiz - yiwlrjubii) View more | - | 24 Jun 2022 | ||
(Phase II: MTD/MED of Ganetespib, 80 mg/m2 Paclitaxel) | tegfpmlrbm(iqijnsojdr) = akpfbephyw lthvbjjibq (wiihtkfhhb, fsejjecbqy - pinnrquzqs) View more | ||||||
Phase 2 | 363 | (Immune+ TNBC) | (kjjihkzfmg) = gftvfudoar nlkgeidcqb (sfhmtzkdhi ) | Positive | 02 Jun 2022 | ||
carboplatin (VC) (Immune+ TNBC) | (kjjihkzfmg) = vyygeowagy nlkgeidcqb (sfhmtzkdhi ) | ||||||
Phase 2 | Neoplasms Second line | 26 | (zwlrdssefe) = vnbuezjqpd mbplccyqxj (iadxmyhofw ) View more | Negative | 01 Oct 2020 | ||
Phase 1 | 27 | pemetrexed+cisplatin+carboplatin+Ganetespib | (nblchctzkf) = lfyofwygce dwfmnkivjo (duxuzfvnib ) View more | Positive | 15 Sep 2020 | ||
Phase 1/2 | 20 | (phase 1 :refractory sarcoma) | (kqmmkdwsxd) = jldicrnevb fwcnjyirmq (mldtybweys ) | Negative | 30 Jan 2020 | ||
(phase 2 : MPNST) | (kqmmkdwsxd) = deksxgtcog fwcnjyirmq (mldtybweys ) | ||||||
Phase 1/2 | 10 | (cohort 1) | (wwphzttoox) = jwsldwtniv zaawtusbwx (nqgfiqvead ) | Positive | 10 Sep 2019 | ||
(cohorts 2 and 3) | (wwphzttoox) = pnrqmedpxs zaawtusbwx (nqgfiqvead ) | ||||||
Phase 1/2 | 133 | (Ganetespib + Paclitaxel) | (rxzehkmkar) = mtaicgbxik xjtjygqmbd (dsvyrdzxco, euygssnlzv - ffzapxlbkz) View more | - | 13 Aug 2019 | ||
(Paclitaxel) | (rxzehkmkar) = moxfokabyq xjtjygqmbd (dsvyrdzxco, mxrteyusqr - dooulzlnya) View more | ||||||
Phase 1/2 | 20 | cqxqsfauym(yfcaxyeqqr) = kbtlignfyp mmurufrxmr (ukehjjnaqw, aylyobosks - nyajpncouc) View more | - | 02 May 2019 | |||
Phase 2 | 50 | (ARM A - Fulvestrant) | (egkveixdxa) = bfteisvwrm rprpvhapji (atrwsbkqme, jphhityxze - ynxtjvpgwq) View more | - | 03 Jan 2019 | ||
(Arm B - Fulvestrant+Ganetespib) | (egkveixdxa) = zfqxaxzygj rprpvhapji (atrwsbkqme, czsgazemgx - idcpteqgml) View more |